16 September 2016 | Features | By BioSpectrum Bureau
BioSpectrum Ranking Survey: Rank 17: Ecron Acunova
Total Revenue: Rs 144.99
Vice Chairman: H R Srinivasan
Ecron Acunova (EA) is a CRO headquartered in Bangalore having global presence across Asia, Europe and USA.
The firm's revenue for the FY 15-16 was Rs 144.99 crore against Rs 135.41 crore in FY 14-15. EA's projected growth for this fiscal is around Rs 156.00 crore, overseas business contributed majority of its revenue (Rs 121.51 crore) while domestic sales contributed around Rs 23.48 crore.
The firm attributes its Asia business growth to more biosimilar studies.
In a major development Ecron acquired Non Interventional Business in Europe.
EA offers services in clinical research from Phase I - IV to pharmaceutical, biotech, nutritional, medical device and diagnostic companies. EA end-to-end services include, but are not limited to trial set-up, clinical trial management, monitoring, clinical data management, medical writing, biostatistics, pharmacovigilance, PK/PD and central lab services, either as a complete service package or as single services on a project basis or as functional outsourcing.
In addition, the firm also launched new service line: Non interventional studies in previous fiscal.
In November 2015, BSE-listed TAKE Solutions, technology solution provider for supply chain and life sciences segments, announced that it has entered into an agreement to acquire Bangalore-headquartered Ecron Acunova (EA), a leading clinical research organisation, in a transaction that is valued at Rs 115 crore.